Myomo (MYO) AI Stock Analysis

• Market Cap: $34.21M
• Dividend Yield: N/A
• Average Volume (3M): 875.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: 64.99%
• EPS Growth: -25.54%
• Country: US
• Employees: 184
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 38,435,524
• 10 Day Avg. Volume: 662,546
• 30 Day Avg. Volume: 875,817
• PEG Ratio: 0.92
• Price to Book (P/B): 9.84
• Price to Sales (P/S): 7.47
• P/FCF Ratio: -52.30
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 0.90
• Enterprise Value/Gross Profit: 1.35
• Enterprise Value/Ebitda: -3.70
• 1Y Price Target: $6.50
• Price Target Upside: 480.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.37
• Revenue Forecast (FY): $39.99M

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-10.71% Downside)

The overall stock score reflects Myomo's financial challenges, including negative profitability and cash flow issues, which weigh heavily on the score. Technical indicators suggest a bearish trend, further impacting the score. While the earnings call provided some positive insights into revenue growth and strategic initiatives, the ongoing financial difficulties and valuation concerns remain significant obstacles.

Positive Factors

Revenue Growth

Consistent revenue growth, especially in international markets, indicates strong demand and effective market expansion strategies.

Strategic Initiatives

Strategic initiatives like MyoConnect and O&P channel expansion aim to reduce costs and enhance patient acquisition, supporting long-term growth.

International Market Success

Strong international performance, especially in Germany, highlights Myomo's ability to penetrate and grow in new markets.

Negative Factors

High Cash Burn

High cash burn rate poses a risk to financial stability, necessitating improved cash flow management to sustain operations.

Decreased Gross Margin

Declining gross margins due to increased costs can pressure profitability, requiring cost control measures to maintain margins.

Increased Operating Loss

Rising operating losses highlight ongoing financial challenges, underscoring the need for operational efficiency improvements.

Myomo Business Overview & Revenue Model

Company Description

Myomo, Inc. (MYO) is a medical technology company that specializes in the development of innovative wearable solutions for individuals with neuromuscular disorders. The company focuses primarily on creating advanced powered orthotics, specifically myoelectric braces, designed to restore mobility and enhance the quality of life for patients suffering from conditions such as stroke, spinal cord injury, and other neurological impairments. Myomo's flagship product, the MyoPro, is a lightweight, non-invasive device that detects muscle signals and translates them into movement, allowing users to regain functional use of their arms and hands.

How the Company Makes Money

Myomo generates revenue primarily through the sale of its MyoPro orthotic devices, which are sold directly to healthcare providers and through various distribution channels. The company also benefits from reimbursement programs that allow patients to have their MyoPro devices covered by insurance, which significantly enhances market access and sales potential. Additionally, Myomo collaborates with healthcare institutions and rehabilitation centers to provide customized solutions and services, further expanding its reach and revenue potential. Strategic partnerships with medical professionals, rehabilitation facilities, and insurance providers play a crucial role in driving sales and increasing the adoption of its products.

Myomo Financial Statement Overview

Summary

Myomo is experiencing revenue growth, but profitability and cash flow challenges persist. The company has increased its leverage, which could pose risks if not managed carefully. Improving operational efficiency and cash flow generation are critical for enhancing financial stability and long-term success.

Income Statement

The company has shown consistent revenue growth, with a TTM revenue growth rate of 2.17%. However, profitability remains a challenge, as indicated by negative net profit and EBIT margins. The gross profit margin is relatively strong at 69.24%, but the company needs to address its operational inefficiencies to improve overall profitability.

Balance Sheet

The debt-to-equity ratio has increased to 0.71 in the TTM period, indicating a rise in leverage. Return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly provided, but the balance sheet shows a moderate level of equity relative to total assets. The company needs to manage its debt levels and improve its equity position.

Cash Flow

Cash flow remains a significant concern, with negative operating and free cash flows. The free cash flow to net income ratio is above 1, indicating that cash flow is less negative than net income, but the overall cash flow position is weak. The company must focus on improving cash generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.64M	32.55M	19.24M	15.56M	13.86M	7.58M
Gross Profit	27.72M	23.19M	13.18M	10.25M	10.31M	4.98M
EBITDA	-10.10M	-5.04M	-7.71M	-10.13M	-9.93M	-10.98M
Net Income	-12.02M	-6.18M	-8.15M	-10.72M	-10.37M	-11.56M
Balance Sheet
Total Assets	34.08M	42.24M	14.58M	10.16M	20.10M	14.71M
Cash, Cash Equivalents and Short-Term Investments	12.55M	24.87M	8.87M	5.35M	15.52M	12.24M
Total Debt	12.30M	8.11M	601.30K	553.91K	735.00K	173.44K
Total Liabilities	19.45M	17.53M	5.59M	3.80M	4.69M	3.14M
Stockholders Equity	14.63M	24.71M	8.99M	6.36M	15.41M	11.57M
Cash Flow
Free Cash Flow	-13.85M	-4.65M	-6.32M	-10.35M	-9.87M	-9.08M
Operating Cash Flow	-10.01M	-3.29M	-6.17M	-10.23M	-9.55M	-9.03M
Investing Cash Flow	-3.82M	259.98K	-2.03M	-310.79K	-326.46K	-45.75K
Financing Cash Flow	19.68M	20.93M	9.71M	376.86K	13.17M	16.78M

Myomo Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.12
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYO, the sentiment is Neutral. The current price of 1.12 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.94, and below the 200-day MA of 2.55, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 58.97 is Neutral, neither overbought nor oversold. The STOCH value of 82.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MYO.

Myomo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ECOR	59 Neutral	$37.98M	―	-337.84%	―	27.90%	1.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYO	44 Neutral	$34.21M	―	-100.51%	―	64.99%	-25.54%
RBOT	39 Underperform	$30.45M	-0.46	-148.93%	―	―	15.03%
ADGM	39 Underperform	$17.79M	―	-210.36%	―	-70.54%	70.03%
IINN	35 Underperform	$32.95M	-2.32	―	―	―	―

Myomo Corporate Events

Myomo Inc. Reports Q3 Revenue Growth Amid Losses

Myomo Inc., a wearable medical robotics company, specializes in developing myoelectric orthotics for individuals with neuromuscular disorders, primarily serving the healthcare sector with its FDA-registered MyoPro product. In its latest earnings report, Myomo Inc. highlighted a revenue increase to $10.1 million for the third quarter of 2025, up from $9.2 million in the same period last year, driven by strong sales in both direct-to-patient and clinical provider channels. Despite this growth, the company reported a net loss of $3.7 million for the quarter, reflecting increased operating expenses, particularly in research and development, and selling and marketing activities. The company’s financial position shows a decrease in cash reserves from $24.4 million at the end of 2024 to $12.6 million as of September 2025, alongside an increase in accounts receivable and inventories, indicating a strategic focus on expanding market presence and product availability. Looking ahead, Myomo’s management remains focused on achieving positive cash flow and sustaining operations through strategic financing and market expansion, while navigating the challenges of reimbursement and competitive pressures in the medical device industry.

Myomo Secures $17.5 Million Loan for Growth

On November 4, 2025, Myomo, Inc. entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. and Avenue Venture Opportunities Fund II, L.P., securing up to $17.5 million in term loans. This financial arrangement aims to support Myomo’s operational needs, including repaying existing borrowings and general corporate purposes. The company reported a strong third quarter in 2025, with revenues reaching $10.1 million, a 10% increase from the previous year, driven by record levels in both U.S. and international O&P revenues. Despite a decrease in gross margin due to higher costs, Myomo is focusing on cost reduction projects and strategic marketing initiatives like MyoConnect to enhance its patient pipeline and reduce costs.

The most recent analyst rating on (MYO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Myomo stock, see the MYO Stock Forecast page.

Myomo Inc. Earnings Call: Growth Amid Challenges

The recent earnings call for Myomo Inc. was a mixed bag of strong growth and notable challenges. The company reported impressive revenue growth and international expansion, particularly in Germany, alongside a record number of pipeline additions. However, these positives were tempered by issues with lead quality and conversion rates, increased operating expenses, and a dip in Medicare Advantage revenue. Myomo is actively addressing these challenges through strategic adjustments, including cost-cutting measures and changes in advertising strategy.

Myomo, Inc. Reports Q2 2025 Financial Results

Myomo, Inc. is a wearable medical robotics company specializing in devices that enhance arm and hand function for individuals with neurological disorders and upper-limb paralysis. The company is known for its MyoPro product line, which is unique in its ability to restore arm function using non-invasive sensors to detect EMG signals.